TIME TO REBOUND IN JOINT SYMPTOMS FOLLOWING DISCONTINUATION OF TNFI THERAPY AFTER ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN PSORIATIC ARTHRITIS PATIENTS ENROLLED IN THE US CORRONA REGISTRY

被引：0
|
作者：
Harrold, L. R. [1 ]
Stolshek, B. [2 ]
Rebello, S. [1 ]
Collier, D. [2 ]
Mutebi, A. [2 ]
Wade, S. W. [3 ]
Malley, W. [1 ]
Greenberg, J. D. [1 ]
Etzel, C. J. [1 ]
机构：
[1] Corrona LLC, Southborough, MA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Wade Outcomes Res Consulting, Salt Lake City, UT USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.1324
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0423
引用
收藏
页码：342 / 343
页数：2
相关论文
共 34 条
  • [31] The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)
    Zhao, Juan
    Zhou, Wei
    Wu, Yangfeng
    Ji, Ping
    Yang, Li
    Yan, Xiaoyan
    Zhang, Zhuoli
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2021, 21 (01)
  • [32] The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)
    Juan Zhao
    Wei Zhou
    Yangfeng Wu
    Ping Ji
    Li Yang
    Xiaoyan Yan
    Zhuoli Zhang
    BMC Medical Informatics and Decision Making, 21
  • [33] EFFECTIVENESS OF A RANDOMIZED STEP-DOWN TO METHOTREXATE OR LEFLUNOMIDE MAINTENANCE THERAPY IN PATIENTS WITH LOW DISEASE ACTIVITY, 40 WEEKS AFTER STARTING COMBINED METHOTREXATE-LEFLUNOMIDE REMISSION INDUCTION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE CARERA TRIAL
    Stouten, V.
    Michiels, S.
    Belba, A.
    Westhovens, R.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 967 - 968
  • [34] Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II) Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
    Shimizu, Toshimasa
    Kawashiri, Shin-Ya
    Sato, Shuntaro
    Morimoto, Shimpei
    Minoda, Shuri
    Kawazoe, Yurika
    Kuroda, Shohei
    Tashiro, Shigeki
    Sumiyoshi, Remi
    Hosogaya, Naoki
    Yamamoto, Hiroshi
    Kawakami, Atsushi
    MEDICINE, 2020, 99 (32) : E21480
1234